Global Opioid Induced Constipation (OIC) Drugs Market Size study, by Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), by Prescription Type (Over The Counter Drugs, Prescribed Drugs), by Distribution Channel (Hospital Phar

Global Opioid Induced Constipation (OIC) Drugs Market Size study, by Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), by Prescription Type (Over The Counter Drugs, Prescribed Drugs), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Store and Retail Pharmacies) and Regional Forecasts 2022-2032

The Global Opioid Induced Constipation (OIC) Drugs Market is valued approximately at USD 1.21 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.01 % over the forecast period 2024-2032. Opioid-induced constipation (OIC) arises primarily due to opioids activating enteric receptors, which subsequently heighten tonic non-propulsive contractions within the intestines, thereby increasing colonic fluid absorption and leading to stool desiccation. Furthermore, opioids tend to elevate the anal sphincter tone and lower the rectal sensory threshold, contributing to tougher stools and less frequent, inefficient defecation. This market encompasses various drugs and treatments designed to manage constipation induced by opioid usage. Growth and innovation within the pharmaceutical industry, driven by a substantial pool of health-conscious consumers, present opportunities for the OIC drugs market share. The market's expansion is anticipated to be propelled by emerging markets, improved healthcare infrastructure, unmet healthcare needs, increasing prevalence of chronic pain in adults, and a rising demand for novel drugs to manage OIC disorders.

The healthcare sector in emerging economies is evolving rapidly, spurred by a growing demand for enhanced healthcare services, significant government investments to upgrade healthcare infrastructure, and the development of the medical tourism industry. E-commerce has become an indispensable tool for businesses globally, driven by the consumer preference for online shopping over traditional purchasing methods. Various health apps with animations to educate the public about OIC and available treatment options have further contributed to the market growth. The demand for effective OIC medications extends beyond developed countries, reaching developing nations like China, Brazil, and India, fueling the market's growth. However, the side effects associated with OIC drugs and the high costs of novel pharmaceuticals, coupled with unfavorable reimbursement policies, act as restraints on market growth. On the contrary, rising R&D activities, increasing regulatory approvals, and higher investments in OIC research are expected to provide lucrative opportunities for market players. Additionally, the demand for novel therapeutics to treat OIC is projected to drive market growth further.


The Opioid-Induced Constipation Market is analyzed across North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. In 2023, North America dominate the market in terms of revenue due to the high prevalence of opioid prescriptions and the growing awareness of related side effects. The region's well-established healthcare infrastructure, coupled with advanced pharmaceutical research and development, supports a robust market for opioid-induced constipation treatments. Additionally, increasing patient awareness and a strong emphasis on addressing the adverse effects of opioid use drive demand for effective management solutions. The presence of major pharmaceutical companies and the availability of innovative therapies further contribute to North America's leading position in this market. Consequently, North America remains a key player in addressing opioid-induced constipation globally. Asia-Pacific is anticipated to grow at the highest rate during the forecast period, attributed to the increasing number of cancer cases, rising awareness campaigns, and investments in effective OIC drugs.

Major market players included in this report are:

AstraZeneca

Bausch Health Companies Inc.

Cosmo Pharmaceuticals

Dr. Reddy’s Laboratories Ltd.

Mallinckrodt plc

Merck & Co., Inc.

Novartis AG

Shionogi & Co., Ltd.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

RedHill Biopharma Ltd.

Sandoz (Novartis AG)

Daiichi Sankyo Co., Ltd.

Pfizer Inc.

Bayer AG


The detailed segments and sub-segment of the market are explained below:

By Drug Type:

Mu-opioid Receptor Antagonists

Chloride Channel-2 Activators

Others

By Prescription Type:

Over The Counter Drugs

Prescribed Drugs

By Distribution Channel:

Hospital Pharmacies

Online Providers

Drug Store and Retail Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.